Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Shafrin

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Blood Advances|May 16, 2025
Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data AnalysisAndrea Chung, Jason Shafrin, Sachin Vadgama, et al.
Future Oncology (London, England)|October 21, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the USErin Mulvey, Jason Shafrin, Kyi-Sin Than, et al.
Forum for Health Economics & Policy|November 8, 2024
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best PracticesJason Shafrin, Jaehong Kim, Joshua T Cohen, et al.
Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Blood Advances|May 16, 2025
Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data AnalysisAndrea Chung, Jason Shafrin, Sachin Vadgama, et al.
Future Oncology (London, England)|October 21, 2025
Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the USErin Mulvey, Jason Shafrin, Kyi-Sin Than, et al.
Forum for Health Economics & Policy|November 8, 2024
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best PracticesJason Shafrin, Jaehong Kim, Joshua T Cohen, et al.
Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.
Pageof 9